Wells Fargo & Company Cuts Enovis (NYSE:ENOV) Price Target to $33.00

Enovis (NYSE:ENOV) had its price target lowered by Wells Fargo & Company from $39.00 to $33.00 in a research report report published on Wednesday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Several other research firms have also commented on ENOV. UBS Group restated a “buy” rating and set a $51.00 price target (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Canaccord Genuity Group decreased their target price on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, August 17th. BTIG Research decreased their target price on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.38.

Enovis Price Performance

Enovis stock opened at $18.58 on Wednesday. The company’s 50 day simple moving average is $25.50 and its 200-day simple moving average is $24.20. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -0.96 and a beta of 1.31. Enovis has a 1 year low of $18.52 and a 1 year high of $34.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same period in the prior year, the business posted $0.79 EPS. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts expect that Enovis will post 3.15 earnings per share for the current year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert purchased 5,140 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was bought at an average price of $19.46 per share, with a total value of $100,024.40. Following the transaction, the insider directly owned 61,238 shares of the company’s stock, valued at approximately $1,191,691.48. This represents a 9.16% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Damien Mcdonald purchased 13,035 shares of the company’s stock in a transaction on Friday, September 4th. The stock was acquired at an average price of $19.15 per share, with a total value of $249,620.25. Following the purchase, the chief executive officer owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 23,833 shares of company stock valued at $469,455 in the last three months. 2.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Arax Advisory Partners acquired a new stake in Enovis in the 4th quarter valued at about $29,000. Allworth Financial LP purchased a new position in shares of Enovis in the 2nd quarter valued at about $36,000. EverSource Wealth Advisors LLC grew its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Enovis during the second quarter worth about $48,000. Finally, Danske Bank A S purchased a new stake in shares of Enovis during the third quarter worth approximately $64,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.